The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Novel Path to Activation of Vascular Smooth Muscle Cells: Up-Regulation of gp130 Creates an Autocrine Activation Loop by IL-6 and Its Soluble Receptor
Abstract
This study describes a novel path to the activation of smooth muscle cells (SMC) by the IL-6/soluble IL-6 receptor (sIL-6R) system. Human vascular SMC constitutively express only scant amounts of IL-6R and so do not respond to stimulation with this cytokine. We show that SMC also do not constitutively express appreciable levels of gp130, which would render them sensitive to transsignaling by the IL-6/sIL-6R complex. Because gp130 is generally believed not to be subject to regulation, SMC would thus appear not to qualify as targets for the IL-6/sIL-6R system. However, we report that treatment of SMC with IL-6/sIL-6R provokes marked up-regulation of gp130 mRNA and surface protein expression. This is accompanied by secretion of IL-6 by the cells, so that an autocrine stimulation loop is created. In the wake of this self-sustaining system, there is a selective induction and secretion of MCP-1, up-regulation of ICAM-1, and marked cell proliferation. The study identifies SMC as the first example of cells in which gp130 expression is subject to substantive up-regulation, and discovers a novel amplification loop involving IL-6 and its soluble receptor that drives SMC into a proinflammatory state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.
Carr, M. W., Roth, S. J., Luther, E., Rose, S. S., & Springer, T. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3652 · Cited by 1,198
Cited by
Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6
Pedersen, B. K., & Febbraio, M. A. (2008) · Physiological Reviews · doi:10.1152/physrev.90100.2007 · Cited by 2,388
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040
Self-citationIL-6 pathway in the liver: From physiopathology to therapy
Schmidt-Arras, D., & Rose-John, S. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.004 · Cited by 881
Self-citationMuscle‐derived interleukin‐6: mechanisms for activation and possible biological roles
FEBBRAIO, M. A., & PEDERSEN, B. K. (2002) · The FASEB Journal · doi:10.1096/fj.01-0876rev · Cited by 875
“Whereas myoblasts have been shown to be capable of producing IL-6 (49, 50), endothelial cells (16), fibroblasts (50), and smooth muscle cells (51) have been shown to produce IL-6 under certain circumstances.”
BackgroundInterleukin-6 Family Cytokines
Rose-John, S. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 799
Self-citationThe two faces of IL-6 in the tumor microenvironment
Fisher, D. T., Appenheimer, M. M., & Evans, S. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.008 · Cited by 693
Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway
Maggio, M., Guralnik, J. M., Longo, D. L., & Ferrucci, L. (2006) · The Journals of Gerontology: Series A · doi:10.1093/gerona/61.6.575 · Cited by 692
Rose-John, S., Scheller, J., Elson, G., & Jones, S. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1105674 · Cited by 647
Self-citationSoluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
Jostock, T., Müllberg, J., Özbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M. F., & Rose‐John, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01867.x · Cited by 641
Self-citationThe soluble interleukin 6 receptor: mechanisms of production and implications in disease
JONES, S. A., HORIUCHI, S., TOPLEY, N., YAMAMOTO, N., & FULLER, G. M. (2001) · The FASEB Journal · doi:10.1096/fj.99-1003rev · Cited by 623
Interleukin-6 and its receptors: a highly regulated and dynamic system
Wolf, J., Rose-John, S., & Garbers, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.024 · Cited by 618
Self-citationMuscle‐derived interleukin‐6: possible biological effects
Pedersen, B. K., Steensberg, A., & Schjerling, P. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.0329c.xd · Cited by 599
“Myoblasts have been shown to be able to produce IL-6 (Bartoccioni et al. 1994; De Rossi et al. 2000), but endothelial cells (Yan et al. 1995), fibroblasts (De Rossi et al. 2000) and smooth muscle (Klouche et al. 1999) have also been shown to produce IL-6 under certain conditions.”
BackgroundTargeting IL-6 trans-signalling: past, present and future prospects
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524
Self-citationSympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress
Dünser, M. W., & Hasibeder, W. R. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609340519 · Cited by 488
The role of IL-6 in host defence against infections: immunobiology and clinical implications
Rose-John, S., Winthrop, K., & Calabrese, L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.83 · Cited by 424
Self-citationPlasticity and cross-talk of Interleukin 6-type cytokines
Garbers, C., Hermanns, H. M., Schaper, F., Müller-Newen, G., Grötzinger, J., Rose-John, S., & Scheller, J. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.04.001 · Cited by 400
Self-citationMatthews, V., Schuster, B., Schütze, S., Bussmeyer, I., Ludwig, A., Hundhausen, C., Sadowski, T., Saftig, P., Hartmann, D., Kallen, K.-J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210584200 · Cited by 390
Self-citationLagathu, C., Bastard, J.-P., Auclair, M., Maachi, M., Capeau, J., & Caron, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.10.013 · Cited by 385
The IL-6/sIL-6R complex as a novel target for therapeutic approaches
Rose-John, S., Waetzig, G. H., Scheller, J., Grötzinger, J., & Seegert, D. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.5.613 · Cited by 360
Self-citationOprée, A., & Kress, M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06289.2000 · Cited by 359
IL-6 biology: implications for clinical targeting in rheumatic disease
Calabrese, L. H., & Rose-John, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.127 · Cited by 328
Self-citationInterleukin-6: from basic biology to selective blockade of pro-inflammatory activities
Scheller, J., Garbers, C., & Rose-John, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2013.11.002 · Cited by 308
Self-citationIL-6 signalling pathways and the development of type 2 diabetes
Akbari, M., & Hassan-Zadeh, V. (2018) · Inflammopharmacology · doi:10.1007/s10787-018-0458-0 · Cited by 302
Interleukin‐6 Trans‐Signalling in Chronic Inflammation and Cancer
Scheller, J., Ohnesorge, N., & Rose‐John, S. (2006) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01750.x · Cited by 297
Self-citationThe soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
Chalaris, A., Garbers, C., Rabe, B., Rose-John, S., & Scheller, J. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.10.007 · Cited by 289
Self-citationHiscock, N., Chan, M. H. S., Bisucci, T., Darby, I. A., & Febbraio, M. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-1259fje · Cited by 273
Jones, S. A., & Rose-John, S. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00319-1 · Cited by 255
Self-citationPlasma and Cerebrospinal Fluid Interleukin-6 Concentrations in Posttraumatic Stress Disorder
Baker, D. G., Ekhator, N. N., Kasckow, J. W., Hill, K. K., Zoumakis, E., Dashevsky, B. A., Chrousos, G. P., & Geracioti Jr., T. D. (2001) · Neuroimmunomodulation · doi:10.1159/000049028 · Cited by 238
Muscle-derived interleukin-6: lipolytic, anti-inflammatory and immune regulatory effects
Pedersen, B. K., Steensberg, A., Keller, P., Keller, C., Fischer, C., Hiscock, N., van Hall, G., Plomgaard, P., & Febbraio, M. A. (2003) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-002-0981-z · Cited by 228
Pedersen, B. K., Steensberg, A., & Schjerling, P. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200105000-00002 · Cited by 223
Barkhausen, T., Tschernig, T., Rosenstiel, P., van Griensven, M., Vonberg, R.-P., Dorsch, M., Mueller-Heine, A., Chalaris, A., Scheller, J., Rose-John, S., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318211ff56 · Cited by 169
Self-citationThe soluble interleukin 6 receptor: advanced therapeutic options in inflammation
Rose‐John, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.782 · Cited by 169
Self-citationRole of Interleukin-6 in Vascular Health and Disease
Villar-Fincheira, P., Sanhueza-Olivares, F., Norambuena-Soto, I., Cancino-Arenas, N., Hernandez-Vargas, F., Troncoso, R., Gabrielli, L., & Chiong, M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.641734 · Cited by 154
JANUS under stress—Role of JAK/STAT signaling pathway in vascular diseases
Grote, K., Luchtefeld, M., & Schieffer, B. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.08.021 · Cited by 128
Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration
Drucker, C., Gewiese, J., Malchow, S., Scheller, J., & Rose-John, S. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.08.003 · Cited by 83
Self-citationSonic hedgehog-dependent activation of adventitial fibroblasts promotes neointima formation
Dutzmann, J., Koch, A., Weisheit, S., Sonnenschein, K., Korte, L., Haertlé, M., Thum, T., Bauersachs, J., Sedding, D. G., & Daniel, J.-M. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx158 · Cited by 49
The Regenerative Activity of Interleukin-6
Galun, E., & Rose-John, S. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-308-4_4 · Cited by 34
Self-citation
Metadata
- Authors
- Klouche, M., Bhakdi, S., Hemmes, M., & Rose-John, S.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-10
- Volume
- 163
- Issue
- 8
- Pages
- 4583-4589
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1487227918
- Cited by
- 178
- References
- 1
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.